SHARE: Simple HAART With Abacavir, Reyataz, and Epivir

An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of a Fixed-Dose Combination of Abacavir 600 mg/Lamivudine 300 mg Once-Daily in Combination With Atazanavir 300 mg + Ritonavir 100 mg Once-Daily in Antiretroviral-Naïve HIV-1 Infected Subjects With Continuing Evaluation of Abacavir/Lamivudine Plus Atazanavir 400 mg for Maintenance Over an Additional 48 Weeks

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00426296

Enrollment

Unknown

Registered

2007-01-24

Start date

2006-08-31

Completion date

Unknown

Last updated

2007-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV Infections, Lipodystrophy

Keywords

HIV, Reyataz, atazanavir, Norvir, ritonavir, Boosted, Lipodystrophy, Treatment Experienced

Brief summary

SHARE: Simple HAART with Abacavir, Reyataz, and Epivir

Detailed description

Open-label, multicenter study of ABC/3TC + ATV in subjects who have completed at least 24 weeks of treatment on ABC/3TC+ATV/RTV as their first line regimen and have plasma HIV-1 RNA \<50 copies/mL at entry

Interventions

DRUGatazanavir (Reyataz)

DRUGritonavir (Norvir)

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* Currently taking abacavir/lamivudine (Epzicom) in combination with atazanavir (Reyataz) boosted with ritonavir (Norvir) as first antiretroviral regimen * Viral load \<50 copies/ml

Exclusion criteria

* Viral load \>50 copies/ml * Having taken more than one antiretroviral regimen

Countries

United States

Contacts

Primary ContactRichard A. Elion, MD

drrelion@aol.com

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026